| Old Articles: <Older 2261-2270 Newer> |
|---|
 |
The Motley Fool
August 5, 2005
Charly Travers |
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders.   |
The Motley Fool
August 5, 2005
Stephen D. Simpson |
Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future. |
BusinessWeek
August 15, 2005
Barrett & Weintraub |
Drugmakers Are Changing Channels All those "Ask your doctor if it's right for you" ads on TV haven't delivered. As drugmakers labor to develop more educational and balanced pitches, they're also trying to better target their messages. |
The Motley Fool
August 4, 2005
Charly Travers |
This One's a Winner Encysive awaits FDA approval, and all signs are positive. Biotech investors, take note. |
Reason
September 2005
Kerry Howley |
Locking Up Life-Saving Drugs U.S. prescription laws make us sicker and poorer because the system that puts drugs over the counter is driven by profits and patents. |
Reason
September 2005
Kerry Howley |
Self-Medicating in Burma The U.S. is the only country in the world that divides drugs into two rigid categories of prescription-only and over-the-counter. Most other developed nations allow for a third class of drugs to be dispensed by a pharmacist, and developing nations typically do not have prescription requirements or fail to enforce them. |
The Motley Fool
August 3, 2005
Stephen D. Simpson |
Pediatrix Is in Good Health A fragmented market, ongoing growth, and proven management spells opportunity for this neonatal intensive care unit services provider. Pediatrix may not look like the cheapest stock, but it's in a very good, growing niche. |
The Motley Fool
August 3, 2005
Charly Travers |
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. |
BusinessWeek
August 8, 2005
Amy Barrett |
BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals. |
The Motley Fool
August 1, 2005
Stephen D. Simpson |
ANSI's Got the Juice While the stock looks expensive based on the current business, future opportunities in markets like meds for Parkinson's disease, essential tremor, migraine, and depression all hold serious potential value. |
| <Older 2261-2270 Newer> Return to current articles. |
